Cancer Family
Secondary Neoplasm
CI-CAN-00000050Explore in graph →
Non-malignant4,276 active trials56 approved drugs532 evidence items
- NCIt
- C36255
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000050Explore in graph →
Clinical trials
14,673 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07313033 | [68]GA-FAPI-46 PET/CT for the Diagnosis of Metastatic Lesions in Patients With Lobular Breast Cancer (ICL).(FAPI-CL) | not yet recruiting | N/A | 45 | Hospices Civils de LyonOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07346404 | Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma(RUBIKID) | not yet recruiting | Phase 2 | 50 | Assistance Publique - Hôpitaux de ParisOTHER | 1 |
| Jan 16, 2026 |
| clinicaltrials |
| NCT07346807 | Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer | not yet recruiting | Phase 2 | 69 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07348107 | ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.(ATARI-PDAC) | not yet recruiting | Phase 1 | 10 | Daniel BreadnerOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07343869 | Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection(FEO) | not yet recruiting | — | 750 | Société Française d'Endoscopie DigestiveOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07345273 | Reporting of Tumour Deposits in Colorectal Cancer by Radiology and Pathology(RADAR) | not yet recruiting | — | 225 | Imperial College LondonOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07341321 | SARS-CoV-2 mRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitors(CoVaCheck) | not yet recruiting | — | 200 | Medical University of GrazOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07337031 | A Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver Cancer | not yet recruiting | N/A | 193 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07337447 | Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)(REWENEC 01) | not yet recruiting | Phase 2 | 122 | Hospices Civils de LyonOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07332533 | A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer | not yet recruiting | Phase 2 / Phase 3 | 490 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Jan 12, 2026 | clinicaltrials |
| NCT07324876 | A Multicenter Real-World Study on TKI Therapy After Progression on First-Line TKI/IO Therapy or TKI/IO Therapy After Progression on First-Line TKI in Chinese Patients With Metastatic Renal Cell Carcinoma (mRCC) | not yet recruiting | — | 860 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07297654 | First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment(FINELAND) | not yet recruiting | Phase 2 | 50 | National Cancer Center, KoreaOTHER_GOV | 0 | Jan 7, 2026 | clinicaltrials |
| NCT07324473 | Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study | not yet recruiting | Phase 2 | 65 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07319949 | Evaluating the Predictive Capability of Transcriptomic Profiling for Identifying the Primary Site of Metastatic Tumors | not yet recruiting | — | 30 | Fudan UniversityOTHER | 0 | Jan 6, 2026 | clinicaltrials |
| NCT07320690 | De-Escalation Surgery After Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma(Neo-Margin) | not yet recruiting | Phase 3 | 356 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07321067 | Use of Immune Checkpoint Inhibitors in Patients With Advanced Hepatocellular Carcinoma : Efficacy and Outcomes(ICIs) | not yet recruiting | — | 75 | Ahmed Karam HelmyOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07309419 | A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma(Cocktail-001) | not yet recruiting | Phase 2 / Phase 3 | 222 | Shanghai Zhongshan HospitalOTHER | 0 | Dec 30, 2025 | clinicaltrials |
| NCT07310771 | Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase II | not yet recruiting | Phase 2 | 23 | Fujian Cancer HospitalOTHER_GOV | 0 | Dec 30, 2025 | clinicaltrials |
| NCT07310836 | A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Hepatocellular Carcinoma Beyond UCSF Criteria Before Liver Transplantation | not yet recruiting | — | 300 | Ningbo Medical Center Lihuili HospitalOTHER_GOV | 0 | Dec 30, 2025 | clinicaltrials |
| NCT07102056 | 18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms | not yet recruiting | — | 152 | First Affiliated Hospital of Zhejiang UniversityOTHER | 0 | Dec 29, 2025 | clinicaltrials |
| NCT07306481 | The Efficacy of Preoperative Oral Administration of Lactobacillus Reuteri Combined With Preoperative Neoadjuvant/Conversion Immunotherapy in Patients With Primary Resectable Liver Cancer | not yet recruiting | N/A | 40 | Fujian Cancer HospitalOTHER_GOV | 0 | Dec 29, 2025 | clinicaltrials |
| NCT07306546 | Effectiveness of Hydrogen Water Intervention on Acute Oral Inflammation, Oral Microbiota, and Pain Following Free Flap Reconstruction in Patients With Oral Cancer | not yet recruiting | N/A | 36 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 0 | Dec 29, 2025 | clinicaltrials |
| NCT07308379 | Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer | not yet recruiting | — | 1,200 | Fudan UniversityOTHER | 0 | Dec 29, 2025 | clinicaltrials |
| NCT07301229 | A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer | not yet recruiting | Phase 2 | 100 | Shanghai Henlius BiotechINDUSTRY | 0 | Dec 24, 2025 | clinicaltrials |
| NCT07299318 | Multimodal Deep Learning for Lymph Node Metastasis in Thyroid Cancer | not yet recruiting | — | 3,200 | West China HospitalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07299409 | First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients. | not yet recruiting | Phase 2 | 24 | Nathalie LevasseurOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07295002 | Sentinel Node Resection With or Without LECS After Noncurative ESD for EGC(Co-SNARE) | not yet recruiting | N/A | 10 | Region StockholmOTHER_GOV | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07287904 | Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data | not yet recruiting | — | 1,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07289048 | A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy Progression | not yet recruiting | Phase 2 | 35 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Dec 17, 2025 | clinicaltrials |
| NCT05128734 | Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) | not yet recruiting | Phase 2 | 40 | AHS Cancer Control AlbertaOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07281664 | Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma | not yet recruiting | N/A | 30 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Dec 15, 2025 | clinicaltrials |
| NCT07282509 | Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer | not yet recruiting | Phase 1 / Phase 2 | 116 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Dec 15, 2025 | clinicaltrials |
| NCT07277972 | Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy | not yet recruiting | Phase 2 | 36 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 11, 2025 | clinicaltrials |
| NCT07271992 | TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer(TREND-02) | not yet recruiting | Phase 2 | 30 | First Hospital of China Medical UniversityOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT07272291 | A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 48 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT07273279 | ADH1B and ALDH Gene Variants and Lung Cancer Risk(ALDH) | not yet recruiting | — | 100,000 | Kaohsiung Medical UniversityOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT07269574 | Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance | not yet recruiting | — | 600 | Tongji HospitalOTHER | 0 | Dec 8, 2025 | clinicaltrials |
| NCT07268469 | Minimal Residual Disease in Solid Malignancies(IMRD) | not yet recruiting | N/A | 840 | European Institute of OncologyOTHER | 0 | Dec 5, 2025 | clinicaltrials |
| NCT07233668 | Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC(IVE in mRCC) | not yet recruiting | N/A | 172 | Seoul National University HospitalOTHER | 0 | Dec 3, 2025 | clinicaltrials |
| NCT07258797 | Short Course or Long Course Radiotherapy as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer(SHOOL) | not yet recruiting | N/A | 150 | Rajiv Gandhi Cancer Institute & Research Center, IndiaOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07259915 | Multimodal Prediction of Response to Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck(MULTINECK) | not yet recruiting | N/A | 152 | Centre Henri BecquerelOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07252661 | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 40 | AccSalus Biosciences, Inc.INDUSTRY | 0 | Nov 28, 2025 | clinicaltrials |
| NCT07253220 | TAF Monotherapy Versus ETV Combined With TAF on the Efficacy and Prognosis of Immunotherapy for Hepatitis B-Related Hepatocellular Carcinoma | not yet recruiting | N/A | 120 | Sun Yat-sen UniversityOTHER | 0 | Nov 28, 2025 | clinicaltrials |
| NCT07251062 | A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. | not yet recruiting | Phase 2 / Phase 3 | 737 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Nov 26, 2025 | clinicaltrials |
| NCT07251829 | Neoadjuvant Embolization and Cytoreduction in Prostate Cancer | not yet recruiting | Phase 2 | 35 | Srinivas RamanOTHER | 0 | Nov 26, 2025 | clinicaltrials |
| NCT06400160 | Clinical Trial of TB511 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 12 | Twinpig Biolab, Inc.INDUSTRY | 0 | Nov 25, 2025 | clinicaltrials |
| NCT07243951 | Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma | not yet recruiting | Phase 2 | 75 | Shanghai Zhongshan HospitalOTHER | 0 | Nov 24, 2025 | clinicaltrials |
| NCT07245316 | Avoiding Surgery in Estrogen Receptor Positive Atypical Ductal Hyperplasia and In-situ Carcinoma Treated With Endocrine Treatment Trial(ASAIN) | not yet recruiting | N/A | 340 | Jeong Eon LeeOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07246330 | Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study | not yet recruiting | Phase 3 | 340 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 24, 2025 | clinicaltrials |
| NCT07246759 | Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis(NEUTROFLOW) | not yet recruiting | — | 600 | OncoHost Ltd.INDUSTRY | 3 | Nov 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 16, 2026source: clinicaltrials